Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742259 | 0.92 | SCD (0.49) | SCDLMNACNR2RAB9ANPC1 | |
| SCHEMBL1740036 | 0.87 | LMNA (0.46) | SCDLMNACNR2RAB9ANPC1 | |
| SCHEMBL3970574 | 0.84 | MAPT (0.47) | SCDCNR2RAB9ANPC1MEN1 | |
| SCHEMBL13648866 | 0.81 | SCD (0.56) | SCDLMNACNR2RAB9ANPC1 | |
| SCHEMBL1744270 | 0.81 | NPC1 (0.42) | SCDRAB9ANPC1MEN1KMT2A | |
| SCHEMBL16013344 | 0.80 | SCN9A (0.40) | KDM2B | |
| Hydrochloric Acid SCHEMBL3971198 | 0.80 | SCD (0.55) | SCDLMNACNR2RAB9ANPC1 | |
| SCHEMBL1742433 | 0.80 | SCD (0.52) | SCDRAB9ANPC1MEN1KMT2A | |
| SCHEMBL13648802 | 0.79 | SCD (0.54) | SCDLMNACNR2RAB9ANPC1 | |
| SCHEMBL3970310 | 0.79 | LMNA (0.45) | LMNARAB9ANPC1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | SCD 3788/4885LMNA 4775/4885CNR2 26/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | SCD 3788/4885LMNA 4775/4885CNR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.